Literature DB >> 25629984

Age influences post-graft-versus-host disease non-relapse mortality in adults with acute graft-versus-host disease of varying severity following allogeneic hematopoietic cell transplant.

Takahiko Nakane1,2, Takahiro Fukuda2,3, Junya Kanda2,4, Shuichi Taniguchi5, Tetsuya Eto6, Kazuteru Ohashi7, Hirohisa Nakamae1, Mineo Kurokawa8, Takehiko Mori2,9, Yasuo Morishima2,10, Tokiko Nagamura-Inoue11, Hisashi Sakamaki7, Yoshiko Atsuta12, Makoto Murata2,13.   

Abstract

We retrospectively analyzed 2682 patients who developed grade II-IV acute graft-versus-host disease (GVHD). On analysis with stratification into five age groups (20-29, 30-39, 40-49, 50-59 and ≥60), 2-year non-relapse mortality rates (NRM) after the onset of GVHD were 20.7, 26.2, 26.6, 37.0 and 40.4%, respectively (p<0.001). We found a significant interaction between the patient's age and GVHD severity with respect to NRM (p=0.004). On multivariate analyses stratified by GVHD severity, the hazard ratio (HR) for NRM in the groups aged 50 years or more (reference: age group 20-29) was about twice as great in patients with grade II acute GVHD when compared with grade III-IV disease (HR in those aged 50-59 years: 2.9 for grade II and 1.5 [p=0.03 and 0.04] for grades III-IV; HR if ≥60 years: 3.3 for grade II and 1.5 for grades III-IV [p<0.001 for both]).

Entities:  

Keywords:  Clinical results; graft-versus-host disease; transplant toxicity

Mesh:

Year:  2015        PMID: 25629984     DOI: 10.3109/10428194.2015.1009056

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  4 in total

1.  Defining vulnerability in allogeneic transplants is more complicated than the two numerical digits of age.

Authors:  Mohamed L Sorror
Journal:  Leuk Lymphoma       Date:  2015-05-20

Review 2.  Prophylactic and therapeutic treatment of graft-versus-host disease in Japan.

Authors:  Makoto Murata
Journal:  Int J Hematol       Date:  2015-04-12       Impact factor: 2.490

Review 3.  Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia of the Elderly: Review of Literature and New Perspectives.

Authors:  Gabriele Magliano; Andrea Bacigalupo
Journal:  Mediterr J Hematol Infect Dis       Date:  2020-11-01       Impact factor: 2.576

4.  Not all patients with AML over 60 years of age should be offered early allogeneic stem cell transplantation.

Authors:  H Joachim Deeg
Journal:  Blood Adv       Date:  2022-03-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.